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RESEARCH ARTICLE
Increased Prevalence 12308 A > G mutation in Mitochondrial tRNALeu (CUN) Gene 
Associated with earlier Age of Onset in Friedreich Ataxia
Abstract
Objectives
Friedreich ataxia (FRDA) is an inherited recessive disorder. Mitochondrial DNA 
is a candidate modifying factor for FRDA.
The purpose of this study was to investigate the relationship between the 
tRNALeu (CUN)  12308 A> G mutation and age of onset in Friedreich ataxia.
Materials & Methods
The 12308 A> G substitution in mitochondrial tRNALeu (CUN) was examined in 
DNA samples from 30 Friedreich ataxia patients and 48 control subjects by 
temporal temperature gradient gel electrophoresis (TTGE) and sequencing. 
Logistic regression was used to determine of cutoff age of onset.
Results
Twenty-two patients had  the 12308 A> G mutation, and we found that its 
overall prevalence was significantly higher in 20 patients aged 17 years or 
younger than in 2 patients aged over 17 years (90% versus 10%). The 12308 A> 
G mutation lies in a region that has been highly conserved between species. 
Conclusion
Our results show that  the 12308 A > G mutation is associated with earlier age 
of onset in Friedreich ataxia. Thus, this mutation might cause the younger age 
of onset in FRDA. 
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Introduction
Friedreich Ataxia (FRDA) is a progressive neurodegenerative disease that results 
from a deficiency in frataxin, a protein that localizes to mitochondria. In typical 
FRDA patients, the gene has undergone a triplet (GAA) expansion in the first intron 
(1, 2). The progressive gait and limb ataxia, hypertrophic cardiomyopathy, and 
diabetes mellitus in FRDA patients are attributed to lowered levels of ATP that are 
generated in these energy-intensive tissues (3). The FRDA gene encodes a widely 
expressed 210-aa protein, frataxin, which is located in mitochondria and is severely 
reduced in FRDA patients (4). Yeast strains that carry a disruption in the Frataxin 
homolog (YFH1) develop a severe defect in the mitochondrial respiration chain 
(RC) and experience a loss in mitochondrial DNA (mtDNA) (5, 6) that is associated 
with elevated intramitochondrial iron (7-9). mtDNA is considered a candidate 
modifying factor for FRDA. Dysfunction of the mitochondrial respiratory chain 
is observed in patients with neurological diseases, including Alzheimer disease 
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(10), Parkinson disease (11), multiple sclerosis (12), and 
Friedreich ataxia (13, 14). tRNALeu (CUN) encodes for the 
most common amino acid in the mt-respiratory chain, 
implicating it in mtDNA-coded OXPHOS subunits. 
Van den Ouweland et al. identified a mutation in the 
mitochondrial tRNALeu (CUN) gene in Chronic Progressive 
External Ophtalmoplegia (CPEO) and Wolfram 
syndrome (15). 
The purpose of this study was to investigate the 
relationship between the tRNALeu (CUN)  12308 A> G 
mutation and age of onset in Friedreich ataxia.
Materials & Methods
Patients
We studied 30 Iranian patients (14 females and 16 males) 
from 30 unrelated families with a diagnosis of FRDA, 
based on their clinical aspects, essentially adopting the 
clinical criteria of Harding and Geffroy et al. (16, 17). 
We also enrolled 48 healthy controls (23 females and 
25 males) who were matched for age, sex, and ethnicity. 
Control subjects had no signs of FRDA on enrollment. 
All patients and control subjects were informed on 
the aims of the study and gave their informed consent 
for participation in the genetic analysis. Patients were 
referred for assessment by consultant neurologists in 
Iran.
Molecular Analysis
DNA was isolated from peripheral blood samples using 
a DNA extraction kit (DNAfast Kit-Genfanavaran, 
Tehran, Iran). The GAA repeat length was calculated per 
Campuzano et al. 1996 (18, 19). The tRNALeu (CUN) gene was 
amplified by PCR in 25 µl using 2 primers (nt 11901-11920 
(F) 5’-TGCTAGTAACCACGTTCTCC-3’ and nt 12420-
12401 (R) 5’-TTTGTTAGGGTTAACGAGGG-3’). The 
reaction mixture comprised 2.5 mM MgCl2, 200 µM of 
each dNTP, 10 pmol of each primer, 100 ng total DNA, 
and 1 U Taq DNA polymerase (Roche Diagnostics, 
Mannheim, Germany). The PCR reactions were 
performed in thermal cyclers (Eppendorf, master cyclers, 
5330) for 30 cycles as follows: 95ºC for 50 s, 57ºC for 
1 min, and 72ºC for 55 s. After the reactions, the PCR 
product (519 bp) was separated on 1.5% agarose gels.
Temporal temperature gradient gel electrophoresis 
(TTGE)
The PCR product (519 bp) was denatured at 95°C for 
30 s and cooled slowly to 45°C for 45 min at 1.1°C/
min. TTGE was performed per the manufacturer›s 
instructions (Dcode Universal Mutation Detection 
Systems, BioRad, Hercules, CA). A volume of 10 µL of 
the denatured and reannealed PCR products was loaded 
onto the gel and electrophoresed at 140 V for 5-6 h as 
the temperature was ramped at 1-2°C/h. The temperature 
range was determined by computer simulation (WinMelt 
software; Bio-Rad Laboratories). The DNA fragments 
from controls and patients were analyzed and compared. 
Any DNA fragments that showed differences in banding 
patterns between controls and patients were sequenced 
to identify the exact mutations (19). If a band shift or 
length heteroplasmy pattern was detected by TTGE, it 
was confirmed by direct DNA sequencing on an ABI 
3700 capillary sequencer (Macrogene Seoul, South 
Korea). Sequences were compared with a comprehensive 
mitochondrial databank (20).
Restriction enzyme analysis
A 144-bp fragment encompassing the tRNALeu (CUN) 
mutation site, located at nt 12,308, was amplified by 
mispairing PCR (15) (primers nt 12,190-12,209 (f) and nt 
12,338-12,309 (r)). The reverse 30-mer oligonucleotide 
(5’- ATTACTTTTATTTGGAGTTGCACCAGAATT) 
contains a nucleotide that differs from the Cambridge 
mtDNA sequence (21) (A to G substitution; underlined in 
the oligonucleotide sequence). This modification created 
an EcoRI site. The mtDNA fragment was digested with 
EcoRI for 1 hour at 37°C, and the fragments (119 and 25 
bp) were separated on a 2.5% agarose gel. Bands were 
visualized by ethidium bromide staining.
Statistical analysis
Fisher’s exact probability test was used to examine the 
association between two groups and to find the relation 
between the 12308 A> G mutation and earlier age of 
onset in Friedreich ataxia. Logistic regression was used 
to determine the cutoff age of onset. When we fit the 
logistic regression to observations, we obtained a cutoff 
point 17. P <0.05 was regarded as statistically significant. 




The age range of patients and controls was 8-32 and 11-
34 years, respectively. The age of FRDA onset in our 
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patients was 13.6 ± 4.8 years (mean ± SD). TTGE analysis 
was performed for 30 patients and 48 healthy controls. 
Our 30 patients were homozygous for an expanded 
(GAA)n repeat in the FRDA gene. The size of the GAA 
expansion in patients was 634 ± 242 repeate (mean ± 
SD), ranging from 243 to 967 GAA repeats. All patients 
presented with the classical Friedreich ataxia phenotype, 
with absence of tendon reflex. Normal controls of the 
same ethnicity were also genotyped to establish the 
frequency of mutations. DNA fragments that showed 
abnormal banding patterns by TTGE analysis were 
sequenced to identify the exact mutations (Figure 1). 
The analyzed mtDNA sequences were compared with 
those of the published sequence (20).
Twenty-two of 30 FRDA patients had a homoplasmic 
 12308 A> G mutation. A subsequent analysis by 
mispairing PCR showed that this mutation was 
homoplasmic in blood from the 5 patient’s mother 
(healthy individual) and 3 healthy controls (Figure 2). 
The data showed that the homoplasmic  12308 A> G 
mutation in FRDA samples was more frequent than in 
normal controls (P = 0.000).
Discussion
The expansion of the GAA repeat in intron 1 of the 
FRDA gene results in a reduction in frataxin expression. 
Although skeletal muscle cell involvement is not a 
prominent clinical feature of patients with FRDA, it 
has been shown that frataxin is absent from or severely 
reduced in skeletal muscle cells in FRDA patients, 
although frataxin mRNA is normally expressed at 
intermediate levels (18, 19, 22). Houshmand et al. 
demonstrated that the rate of D-loop variations was 
higher in FRDA patients than controls (P < 0.05); 
mtDNA deletions were present in 76% of our patients 
who presented with mtDNA damage, which may be due 
to the accumulation of iron in mitochondria (23). We 
suggested previously that our patients had a biochemical 
defect in complex I activity and ATP production (24) 
and several point mutations in mitochondrial ND genes 
(25). In 22 patients with the 12308 A>G mutation, the 
overall prevalence of this mutation was significant 
higher in the 20 patients aged 17 years or younger than 
in the 2 patients aged over 17 years (90% versus 10%, 
represented P = 0.000) (Figure 3). Note that the cutoff 
point, 17 years, is the earlier age of onset for which the 
probability of having the 12308 A> G mutation is 0.5. 
When we analyzed GAA repeats in these 22 patients, 
that mean ± SD of longer GAA repeats in patients aged 
17 years or younger was higher than those aged 17 years 
(691 ± 142 versus 468 ± 188, represented P = 0.01). The 
tRNALeu (CUN) sequence and the two-dimensional (2D) 
structure comparison, per the Mamit-tRNA database 
(http://mamit-tRNA.u-strasbg.fr), showed  that the 12308 
A > G mutation is highly conserved between species. 
 The 12308 A > G mutation is found in breast cancer (26), 
and Pulkes et al. reported an increased risk of stroke that 
is associated with the presence of a homoplasmic 12308 
A > G variant in 48 patients (27). Iron accumulation 
in the mitochondria of patients with FRDA results in 
hypersensitivity to oxidative stress as a consequence 
of a Fenton reaction. (Fe2+-catalyzed production of 
hydroxyl radicals). As reactive oxygen species (ROS) 
are continuously generated by the respiratory chain, 
they may cause significant oxidative damage to mtDNA 
(such as mtDNA deletions and mutations) if they are not 
efficiently eliminated (28).
More than 60 different pathogenic mutations and 
more than 50 polymorphic sites have been described 
in these tRNA genes (see also http://www.gen.emory.
edu/mitomap.html). The difficulties in deciding to what 
extent mtDNA (and nuclear DNA) analyses should be 
performed in patients with RC deficiencies underscore 
the importance of investigating a large group of 
patients for the presence of pathogenic mitochondrial 
mutations. The tRNALeu (CUN) mutation in MELAS and 
diabetes patients gives rise to severe impairments in 
16S ribosomal RNA transcription termination, resulting 
in an imbalance between the amounts of ribosomal and 
other RNA transcripts (29). The effect of all other tRNA 
gene mutations on the transcription and translation of 
mitochondrial genes has not been investigated. Our 
results show that the  12308 A > G mutation associates 
with earlier age of onset in Friedreich ataxia. It is 
possible that the 12308 A > G mutation in mtDNA is a 
predisposing factor that lowers age of onset in FRDA.
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Figure 1. Detection and Identification of a Homoplasmic  12308A > G Mutation in FRDA 
Patient by TTGE and Sequencing 
 
Lane 1, 2 and 3 homoplasmic band shifts belong to FRDA patients. Lane 4, normal control. 
Sequencing result revealed this mutation. 
 
Figure 2. Detection of tRNALeu (CUN) Mutation by EcoRI Digestion in One Control (Lane 1), 
FRDA Patient and Her Mother (Lane 2 and 3), Control with this Mutation (Lane 4) and One 
Patient and Two Controls Without this Mutation (Lane 5, 6 and 7).  
 
Fragment sizes in base pairs are indicated. 
Fig 1. Detection and Identification of a Homoplasmic  12308 A > G Mutation in FRDA 
Patient by TTGE and Sequencing
Lane 1, 2 and 3 homoplasmic band shifts belong to FRDA patients. Lane 4, normal control. 
Sequencing result revealed this mutation.
Fig 2. Detection of tRNALeu (CUN) Mutation by EcoRI Digestion in One Control (Lane 1), FRDA Patient and 
Her Mother (Lane 2 and 3), Control with this Mutation (Lane 4) and One Patient and Two Controls Without 
this Mutation (Lane 5, 6 and 7). Fragment sizes  in base pairs are indicated.
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Fig 3. The Graph of Probability of Having the 12308 A> G Mutation Versus the Earlier Age of Onset in FRDA
 
Table 1: The Probability of Having the 12308 A > G Mutation with the Earlier Age of Onset for Total of 30 Patients are Used in 
this Clinical Study. This Table Shows That the Probability of Having the 12308 A > G Mutation is Closed to One for the Small 
Values of the Earlier age of Onset. On the Other Hand the Probability of Having the 12308 A > G Mutation Decreased Where the 
Earlier Age of Onset Increased and Vice Versa.
Frequency of Observed Value Probability of Having Mutation Probability of Having no Mutation
Having Mutation Having no Mutation
3 1 0 0.9947 0.0053
5 1 0 0.9893 0.1070
7 1 0 0.9785 0.0215
8 2 0 0.9697 0.0303
9 1 0 0.9574 0.0426
10 1 0 0.9404 0.0596
11 1 0 0.9173 0.0827
12 2 0 0.8862 0.1138
13 4 1 0.8455 0.1545
14 2 2 0.7936 0.2064
15 2 0 0.7298 0.2702
16 1 0 0.6548 0.3452
17 1 1 0.5713 0.4287
18 1 1 0.4835 0.5165
20 0 1 0.3160 0.6840
21 1 0 0.2450 0.7550
22 0 1 0.1857 0.8143
23 0 1 0.1380 0.8620
 
 
Figure 3. The Graph of Probability of Having the 12308 A > G Mutation Versus the Earlier Age 
of Onset in FRDA 
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